Renin-angiotensin system polymorphisms and hemoglobin level in renal allografts: A comparative study between losartan and enalapril

Drug Applied Research Center, Tabriz Medical University, Tabriz, Iran.
Transplantation Proceedings (Impact Factor: 0.98). 06/2007; 39(4):1018-22. DOI: 10.1016/j.transproceed.2007.02.016
Source: PubMed


In this study, hemoglobin (Hb) concentrations secondary to enalapril (E) or losartan (L) therapy were evaluated with respect to renin-angiotensin system (RAS) polymorphisms in renal transplant recipients.
After determination of RAS polymorphisms [angiotensin-converting enzyme (DD, non-DD), angiotensinogen (TT, non-TT), and angiotensin receptor type 1 (CC, non-CC)] by polymerase chain reaction, 70 renal transplant recipients were recruited to four groups randomly: first and second groups were treated with E (10 mg/d, 15 patients) and L (50 mg/d, 20 patients) alone, respectively. The third group received E+L (10 mg/d + 50 mg/d, 13 patients) and the fourth group (22 patients) received no medication. The treatment protocol was followed for 16 weeks. Complete blood counts were checked before treatment and every 2 months. P<.05 was considered to indicate statistical significance.
Treatment for 4 months decreased the Hb level in the E+L (14.15 +/- 0.94 to 12.06 +/- 0.66 g/dL, P=.000), E (14.00 +/- 0.86 to 13.11 +/- 0.82 g/dL, P=.02), and L (14.12 +/- 0.90 to 12.10 +/- 2.35 g/dL, P=.01) groups, but not in the control group (13.55 +/- 0.70 to 13.36 +/- 0.69 g/dL, P>.05). None of these regimens showed greater Hb reduction than the others (P>.05). None of the RAS polymorphisms predicted the intensity of the reduced Hb according to the type of treatment (P>.05). Any other sets of RAS polymorphisms (alone or together) did not impact on Hb levels pre- or post-intervention (P>.05).
Our findings suggest that low dosages of E and/or L decrease Hb levels regardless of the RAS polymorphisms.

6 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: In some nontransplant populations, effects of different antihypertensive drug classes vary. Relative effects in kidney transplant recipients are uncertain. To assess comparative effects of different classes of antihypertensive agents in kidney transplant recipients. MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, conference proceedings and reference lists of identified studies were searched. Randomised controlled trials of any antihypertensive agent applied to kidney transplant recipients for at least two weeks were included. Data was extracted by two investigators independently. Study quality, transplant outcomes and other patient centred outcomes were assessed using random effects meta-analysis. Risk ratios (RR) for dichotomous outcomes and mean difference (MD) for continuous outcomes, both with 95% confidence intervals (CI) were calculated. Stratified analyses and meta-regression were used to investigate heterogeneity. We identified 60 studies, enrolling 3802 recipients. Twenty-nine studies (2262 participants) compared calcium channel blockers (CCB) to placebo/no treatment, 10 studies (445 participants) compared angiotensin converting enzyme inhibitors (ACEi) to placebo/no treatment and seven studies (405 participants) compared CCB to ACEi. CCB compared to placebo/no treatment (plus additional agents in either arm as required) reduced graft loss (RR 0.75, 95% CI 0.57 to 0.99) and improved glomerular filtration rate (GFR), (MD, 4.45 mL/min, 95% CI 2.22 to 6.68). Data on ACEi versus placebo/no treatment were inconclusive for GFR (MD -8.07 mL/min, 95% CI -18.57 to 2.43), and variable for graft loss, precluding meta-analysis. In direct comparison with CCB, ACEi decreased GFR (MD -11.48 mL/min, 95% CI -5.75 to -7.21), proteinuria (MD -0.28 g/24 h, 95% CI -0.47 to -0.10), haemoglobin (MD -12.96 g/L, 95% CI -5.72 to -10.21) and increased hyperkalaemia (RR 3.74, 95% CI 1.89 to 7.43). Graft loss data were inconclusive (RR 7.37, 95% CI 0.39 to 140.35). Other drug comparisons were compared in small numbers of participants and studies. These data suggest that CCB may be preferred as first line agents for hypertensive kidney transplant recipients. ACEi have some detrimental effects in kidney transplant recipients. More high quality studies reporting patient centred outcomes are required.
    Cochrane database of systematic reviews (Online) 02/2009; DOI:10.1002/14651858.CD003598.pub2 · 6.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Is assess the effects of angiotensin II type-I receptor blockers on outcomes in renal transplant recipients without proteinuria or posttransplantation erythrocytosis. Fifty renal transplant recipients (30 men and 20 women, with a mean [SD] age of 40 [13] years) were randomized into 2 groups of 25 patients each; 1 group was treated with losartan for 1 year, and the other was not (control group). Blood pressure and other biochemical parameters were measured at baseline and at 6 and 12 months posttransplantation. After 1 year, the losartan group had significantly lower systolic blood pressure (113 [22] mm Hg vs 126 [18] mm Hg; P = .04) and hemoglobin concentration (12.8 [1.9] g/dL vs 14.5 [2.1] g/dL; P = .006) and significantly higher serum high-density lipoprotein cholesterol concentration (58 [22] mg/dL vs 47 [10] mg/dL; P = .03) compared with the control group; however the incidence of anemia did not differ (37% vs 20%; P = .20). In the losartan group, there were significant changes in hemoglobin concentration between baseline and 6 months (14.5 [1.6] g/dL vs 12.9 [1.49] g/dL; P < .001), but not between 6 and 12 months (12.9 [1.49] g/dL vs 12.8 [1.96] g/dL; P = .43). After 1 year, there were no significant between-group differences in diastolic hypertension, serum creatinine concentration, creatinine clearance, and serum potassium, low-density lipoprotein cholesterol, triglyceride, and uric acid concentrations. Losartan significantly increased high-density lipoprotein concentration and significantly decreased systolic hypertension. Although losartan decreased the hemoglobin concentration during the first 6 months, its effect did not progress with longer use. To determine the effect of losartan on renal function, additional studies with longer follow-up are needed.
    Transplantation Proceedings 09/2009; 41(7):2832-4. DOI:10.1016/j.transproceed.2009.07.021 · 0.98 Impact Factor